Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a Continuation of U.S. patent application Ser. No. 15 / 445,461, filed 28 Feb. 2017, which claims the benefit of U.S. Provisional Application Ser. No. 62 / 302,010, filed 1 Mar. 2016, and Great Britain Application No. 1603568.5, filed 1 Mar. 2016, the content of each of these applications is herein incorporated by reference in their entirety.[0002]This application also is related to PCT / EP2017 / 054559 filed 28 Feb. 2017, the content of which is incorporated herein by reference in its entirety.REFERENCE TO SEQUENCE LISTING SUBMITTED AS A COMPLIANT ASCII TEXT FILE (.TXT)[0003]Pursuant to the EFS-Web legal framework and 37 CFR §§ 1.821-825 (see MPEP § 2442.03(a)), a Sequence Listing in the form of an ASCII-compliant text file (entitled “2912919-063002_Sequence_Listing_ST25.txt” created on 27 Jun. 2019, and 32,328 bytes in size) is submitted concurrently with the instant application, and the entire contents of the Sequence List...

AI Technical Summary

Benefits of technology

[0042]The following tables show the peptides according to the present invention, their respective SEQ ID NOs, and the prospective source (underlying) genes for these peptides. All peptides in Table 1 and Table 2 bind to HLA-A*02. The peptides in Table 2 have been disclosed before, but have not been associated with cancer at all bef

Problems solved by technology

BCG treatment is in general well tolerated by patients but can be fatal especially by the immunocompromised patients.

The treatment of patients who failed the BCG therapy is challenging.

The patients who failed the BCG treatment are at high risk for developing of muscle-invasive disease.

In general, the treatment of advanced bladder cancer with muscle invasion known as muscle-invasive bladder carcinoma (MIBC) or metastatic bladder cancer is challenging and remained substantially unchanged over the last few decades.

Nowadays available options for treatment of progressed bladder cancer are insufficiently effective.

The adjuvant application of chemotherapy by the treatment of MIBC is limited by the high surgical complication rate a

Images